We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+2.81%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$39.2B
AUM Growth
+$2.5B
Cap. Flow
+$1.83B
Cap. Flow %
4.67%
Top 10 Hldgs %
16.25%
Holding
3,494
New
280
Increased
1,537
Reduced
1,324
Closed
255

Sector Composition

Rank Sector Weight
1 Technology 9.2%
2 Financials 8.97%
3 Healthcare 8.75%
4 Industrials 7.19%
5 Consumer Staples 6.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
REFR icon
3076
Research Frontiers
REFR
$17.1M
$50K ﹤0.01%
27,500
-500
-2% -$1.03K
BMY icon
3077
CALL
Bristol-Myers Squibb
BMY
$132B
$49K ﹤0.01%
13,600
-39,700
-74% -$2.17M
TEN
3078
Tsakos Energy Navigation Ltd
TEN
$1.18B
$49K ﹤0.01%
+2,107
New +$49.6K
CRDF icon
3079
Cardiff Oncology
CRDF
$75.5M
$48K ﹤0.01%
319
+171
+116% +$39.9K
HOG icon
3080
CALL
Harley-Davidson
HOG
$2.7B
$45K ﹤0.01%
37,800
-5,100
-12% -$291K
KOPN icon
3081
Kopin
KOPN
$797M
$43K ﹤0.01%
15,200
-2,000
-12% -$4.86K
VJET
3082
DELISTED
VOXELJET AG American Depositary Shares (each representing one Ordinary Share)
VJET
$42K ﹤0.01%
2,923
+780
+36% +$15K
BSX icon
3083
CALL
Boston Scientific
BSX
$73.3B
$41K ﹤0.01%
20,000
DVAX
3084
DELISTED
Dynavax Technologies
DVAX
$41K ﹤0.01%
10,482
-330
-3% -$2.42K
GGB icon
3085
Gerdau
GGB
$9.78B
$41K ﹤0.01%
16,380
CLDX icon
3086
Celldex Therapeutics
CLDX
$3.27B
$39K ﹤0.01%
732
-33
-4% -$1.88K
PQ
3087
DELISTED
Petroquest Energy Inc Wd
PQ
$39K ﹤0.01%
11,925
NMM icon
3088
Navios Maritime Partners
NMM
$2.23B
$38K ﹤0.01%
1,780
-467
-21% -$10.5K
CHRD icon
3089
CALL
Chord Energy
CHRD
$7.6B
$37K ﹤0.01%
+11,500
New +$149K
CRNT icon
3090
Ceragon Networks
CRNT
$198M
$37K ﹤0.01%
+14,100
New +$33.8K
HOV icon
3091
Hovnanian Enterprises
HOV
$785M
$37K ﹤0.01%
548
TT icon
3092
CALL
Trane Technologies
TT
$106B
$36K ﹤0.01%
16,500
-300
-2% -$21.6K
FUEL
3093
DELISTED
Rocket Fuel Inc.
FUEL
$36K ﹤0.01%
21,300
-3,950
-16% -$8.26K
GILD icon
3094
CALL
Gilead Sciences
GILD
$164B
$35K ﹤0.01%
16,700
+5,500
+49% +$409K
RJF icon
3095
CALL
Raymond James Financial
RJF
$34.3B
$35K ﹤0.01%
+32,850
New +$1.45M
VCEL icon
3096
Vericel Corp
VCEL
$2.26B
$35K ﹤0.01%
+11,606
New +$29.8K
DD icon
3097
CALL
DuPont de Nemours
DD
$19.1B
$34K ﹤0.01%
10,978
+1,540
+16% +$214K
JBL icon
3098
CALL
Jabil
JBL
$36B
$34K ﹤0.01%
+14,300
New +$312K
PINC
3099
CALL
DELISTED
Premier
PINC
$34K ﹤0.01%
+34,300
New +$1.06M
SNGX icon
3100
Soligenix
SNGX
$5.86M
$34K ﹤0.01%
+62
New +$36K

Similar funds

Raymond James & Associates's Q4 2016 Portfolio in Review

As of Q4 2016, Raymond James & Associates held 3,494 positions worth $39.2B, up 6.8% from $36.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Raymond James & Associates deployed $1.83B of net new capital in Q4 2016, opening 280 new positions and adding to 1,537 existing holdings. Its largest new stake was Invesco S&P 500 High Beta ETF: 442,572 shares worth $16.2M.

By sector, the portfolio is most concentrated in Technology at 9.2% of assets, up from 9.1% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Reynolds American Inc, an estimated $76.5M trimmed.

  • Raymond James & Associates's largest Q4 2016 buy was Invesco S&P 500 High Beta ETF: 442,572 shares worth $16.2M.
  • Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q4 2016, an estimated $118M increase.
  • Raymond James & Associates's biggest Q4 2016 reduction was Reynolds American Inc, cutting an estimated $76.5M.
  • Raymond James & Associates fully exited Amsurg Corp in Q4 2016, selling an estimated $29.2M.
  • Raymond James & Associates's ten largest holdings make up 16% of its $39.2B portfolio in Q4 2016.
  • Raymond James & Associates opened 280 new positions and closed 255 in Q4 2016.
  • Raymond James & Associates's portfolio value rose 6.8% quarter-over-quarter to $39.2B.

Based on Raymond James & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.